DENISE MIYAMOTO

(Fonte: Lattes)
Índice h a partir de 2011
8
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 10 de 11
  • article 124 Citação(ões) na Scopus
    Bullous pemphigoid
    (2019) MIYAMOTO, Denise; SANTI, Claudia Giuli; AOKI, Valeria; MARUTA, Celina Wakisaka
    Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects elderly individuals. Increase in incidence rates in the past decades has been attributed to population aging, drug-induced cases and improvement in the diagnosis of the nonbullous presentations of the disease. A dysregulated T cell immune response and synthesis of IgG and IgE autoantibodies against hemidesmosomal proteins (BP180 and BP230) lead to neutrophil chemotaxis and degradation of the basement membrane zone. Bullous pemphigoid classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense pruritus. Mucosal involvement is rarely reported. Diagnosis relies on (1) the histopathological evaluation demonstrating eosinophilic spongiosis or a subepidermal detachment with eosinophils; (2) the detection of IgG and/or C3 deposition at the basement membrane zone using direct or indirect immunofluorescence assays; and (3) quantification of circulating autoantibodies against BP180 and/or BP230 using ELISA. Bullous pemphigoid is often associated with multiple comorbidities in elderly individuals, especially neurological disorders and increased thrombotic risk, reaching a 1-year mortality rate of 23%. Treatment has to be tailored according to the patient's clinical conditions and disease severity. High potency topical steroids and systemic steroids are the current mainstay of therapy. Recent randomized controlled studies have demonstrated the benefit and safety of adjuvant treatment with doxycycline, dapsone and immunosuppressants aiming a reduction in the cumulative steroid dose and mortality.
  • article 9 Citação(ões) na Scopus
    Diagnostic approach of eosinophilic spongiosis
    (2019) MORAIS, Karina Lopes; MIYAMOTO, Denise; MARUTA, Celina Wakisaka; AOKI, Valeria
    Eosinophilic spongiosis is a histological feature shared by some distinct inflammatory disorders, and is characterized by the presence of intraepidermal eosinophils associated with spongiosis. Most often, isolated eosinophilic spongiosis indicates the early stages of a subjacent autoimmune bullous dermatosis, such as the pemphigus group and bullous pemphigoid. Herein, the main causes of eosinophilic spongiosis are discussed, as well as the supplementary investigation needed to elucidate its etiology. (C) 2019 Published by Elsevier Espana, S.L.U. on behalf of Sociedade Brasileira de Dermatologia.
  • article 2 Citação(ões) na Scopus
    Exfoliative erythroderma as a clinical manifestation of autoimmune bullous diseases
    (2016) MIYAMOTO, Denise; BATISTA, Daniel I. S.; SANTI, Claudia G.; MARUTA, Celina W.; DELGADO, Livia; AOKI, Valeria
  • article 24 Citação(ões) na Scopus
    Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview
    (2019) MARUTA, Celina Wakisaka; MIYAMOTO, Denise; AOKI, Valeria; CARVALHO, Ricardo Comes Ribeiro de; CUNHA, Breno Medeiros; SANTI, Claudia Giuli
    Paraneoplastic pemphigus is a rare and severe autoimmune blistering disease characterized by mucocutaneous lesions associated with benign and malignant neoplasms. Diagnostic criteria include the presence of chronic mucositis and polymorphic cutaneous lesions with occult or confirmed neoplasia; histopathological analysis exhibiting intraepidermal acantholysis, necrotic keratinocytes, and vacuolar interface dermatitis; direct immunofluorescence with intercellular deposits (IgG and C3) and at the basement membrane zone (IgG); indirect immunofluorescence with intercellular deposition of IgG (substrates: monkey esophagus and simple, columnar, and transitional epithelium); and, autoreactivity to desmogleins 1 and 3, desmocollins 1, 2, and 3, desmoplakins I and II, envoplakin, periplakin, epiplakin, plectin, BP230, and alpha-2-macroglobulin-like protein 1. Neoplasias frequently related to paraneoplastic pemphigus include chronic lymphocytic leukemia, non-Hodgkin lymphoma, carcinomas, Castleman disease, thymoma, and others. Currently, there is no standardized treatment for paraneoplastic pemphigus. Systemic corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, rituximab, cyclophosphamide, plasmapheresis, and intravenous immunoglobulin have been used, with variable outcomes. Reported survival rates in 1, 2, and 5 years are 49%, 41%, and 38%, respectively.
  • article 1 Citação(ões) na Scopus
    Recurrent erythema multiforme: A therapeutic proposal for a chronic disease
    (2021) OLIVEIRA, Natasha Favoretto Dias de; MIYAMOTO, Denise; MARUTA, Celina Wakisaka; AOKI, Valeria; SANTI, Claudia Giuli
    Recurrent erythema multiforme is a chronic relapsing disease that represents a therapeutic challenge. Our objective was to retrospectively evaluate the clinical-epidemiological characteristics and therapeutic response of patients with recurrent erythema multiforme and suggest a therapeutic protocol. We included patients with recurrent erythema multiforme diagnosed between January 2000 and December 2019. Clinical symptoms and a positive serology for herpes simplex virus were the inclusion criteria to initiate acyclovir in monotherapy or a combined treatment with dapsone, thalidomide, or immunosuppressants in refractory cases. Thirty-five patients were included and 71.4% were female. The median disease onset age was 35.7 years and the mean follow-up was 7.58 years. The skin was the most affected site (91.4%). Herpes simplex virus immunoglobulin (Ig)G serology was positive in 91.1% of cases. Acyclovir treatment was used in 33 of 35 patients, and complete remission was achieved in 22 of 33 after the first therapeutic course; 16 of 22 relapsed and required a second acyclovir cycle. Combined treatment with dapsone was required in nine of 33 due to partial response to acyclovir; thalidomide was an adjuvant drug in four of 33 due to adverse effects to dapsone. After the first cycle of acyclovir with or without combined therapy, 19 of 33 patients relapsed and received 2-6 additional cycles. Our results suggest that recurrent erythema multiforme presents a good response to acyclovir in monotherapy or in combined therapy with dapsone or thalidomide in the majority of patients. We propose a long-term therapeutic protocol to enable disease remission.
  • article 0 Citação(ões) na Scopus
    Considerations on Immunization and Immunosuppression of Patients With Autoimmune Blistering Diseases During COVID-19 Pandemic in Brazil: Case Report
    (2022) MIYAMOTO, Denise; SANTI, Claudia Giuli; MARUTA, Celina Wakisaka; AOKI, Valeria
    Autoimmune blistering diseases comprise a rare group of potentially life-threatening dermatoses. Management of autoimmune disorders poses a challenge in terms of achieving disease control and preventing adverse events. Treatment often requires an individualized approach considering disease severity, age, comorbidities, and infectious risk especially in the context of the ongoing COVID-19 pandemic. Knowledge regarding SARS-CoV-2 infection is still evolving and no specific antiviral therapy is available yet. We report four patients with active disease that required adjustment of treatment during the pandemic to discuss the use of immunosuppressants and immunobiologics, weighing potential risks and benefits of each therapy modality and vaccination status.
  • conferenceObject
    Increased vascular endothelial growth factor expression in erythrodermic pemphigus foliaceus patients
    (2016) MIYAMOTO, Denise; OTANI, Camila Sayuri Vicentini; FUKUMORI, Ligia Maria Ichimura; PEREIRA, Naiura Vieira; SOTTO, Mirian Nacagami; MARUTA, Celina Wakisaka; SANTI, Claudia Giuli; REBEIS, Marina Mattos; AOKI, Valeria
  • article 7 Citação(ões) na Scopus
    Autoimmune bullous diseases in pregnancy: clinical and epidemiological characteristics and therapeutic approach
    (2021) FAGUNDES, Patricia Penha Silveira; SANTI, Claudia Giuli; MARUTA, Celina Wakisaka; MIYAMOTO, Denise; AOKI, Valeria
    Autoimmune bullous dermatoses are a heterogeneous group of diseases with autoantibodies against structural skin proteins. Although the occurrence of autoimmune bullous dermatoses during pregnancy is low, this topic deserves attention, since the immunological and hormonal alterations that occur during this period can produce alterations during the expected course of these dermatoses. The authors review the several aspects of autoimmune bullous dermatoses that affect pregnant women, including the therapeutic approach during pregnancy and breastfeeding. Gestational pemphigoid, a pregnancy-specific bullous disease, was not studied in this review. (C) 2021 Published by Elsevier Espana, S.L.U. on behalf of Sociedade Brasileira de Dermatologia.
  • conferenceObject
    Mucocutaneous involvement in newborn with congenital epidermolysis bullosa acquisita
    (2016) CORREA, Paula Yume Sato Serzedello; MIYAMOTO, Denise; MARUTA, Celina Wakisaka; AOKI, Valeria; SANTI, Claudia Giuli
  • article 33 Citação(ões) na Scopus
    Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience
    (2014) ARBACHE, Samia Trigo; DELGADO, Livia; AOKI, Valeria; NOGUEIRA, Tarsila Gasparotto; MIYAMOTO, Denise
    BACKGROUND: Immunofluorescence testing is an important tool for diagnosing autoimmune blistering diseases. OBJECTIVE: To characterize the immunofluorescence findings in patients diagnosed with autoimmune blistering skin diseases. METHODS: We retrospectively analyzed immunofluorescence results encompassing a 10-year period. RESULTS: 421 patients were included and divided into 2 groups: group 1-intraepidermal blistering diseases (n=277) and 2-subepidermal blistering diseases (n=144). For group 1, positive DIF findings demonstrated: predominance of IgG intercellular staining (ICS) and C3 for pemphigus foliaceus-PF (94% and 73% respectively), pemphigus vulgaris-PV (91.5%-79.5%) and paraneoplastic pemphigus-PNP (66%-33%); ICS IgA in 100% of IgA pemphigus cases, and IgG deposits in the basement membrane zone (BMZ) along with ICS in one Hailey-Hailey patient. The IIF findings revealed mean titers of 1:2.560 for PV and 1:1.280 for PF. For paraneoplastic pemphigus, IIF was positive in 2 out of 3 cases with rat bladder substrate. In group 2, positive DIF findings included multiple deposits at basement membrane zone for epidermolysis bullosa acquisita-EBA (C3-89%, IgG-79%, IgA-47%, IgM-21%) mucous membrane pemphigoid-MMP (C3, IgG, IgA, IgM-80%) and bullous pemphigoid-BP (C3-91%, IgG-39%, IgA-11%, IgM-6%), and IgA at basement membrane zone for IgA linear disease (99%) and dermatitis herpetiformis-DH (dermal papillae in 84.6%). For lichen planus pemphigoides, there was C3 (100%) and IgG (50%) deposition at basement membrane zone. indirect immunofluorescence positive findings revealed basement membrane zone IgG deposits in 46% of BP patients, 50% for EBA, 15% for IgA linear dermatosis and 50% for LPP. Indirect immunofluorescence positive results were higher for BP and EBA with Salt-Split skin substrate. CONCLUSION: Our results confirmed the importance of immunofluorescence assays in diagnosing autoimmune blistering diseases, and higher sensitivity for indirect immunofluorescence when Salt-split skin technique is performed.